Kauff Appointed Director Of Clinical Cancer Genetics

May 20, 2016
By: Karen E. Butler, Director of Communications, DCI

Noah D. Kauff, MDNoah D. Kauff, MD, recently joined Duke University Health System and Duke University School of Medicine as the director of Clinical Cancer Genetics for the Duke Cancer Institute.

In his newly appointed position, Kauff will provide leadership, strategy and oversight for Clinical Cancer Genetics and the Hereditary Cancer Clinic, which opened in 1999 to offer risk assessment and education to patients with cancer and people with a family history of cancer or other risk factors. Kauff will be responsible for articulating a vision of programmatic excellence for Clinical Cancer Genetics for the Duke Cancer Institute. He will identify the short and long-term objectives required to move the program, which incorporates clinical care, research and education, toward this vision.

Previously, Kauff was director of Ovarian Cancer Screening and Prevention Program in the Gynecology Service, Department of Surgery at Memorial Sloan-Kettering Cancer Center (MSKCC). He was an attending physician for the MSKCC Clinical Genetic Service where his practice encompassed all aspects of cancer risk assessment, genetic counseling and genetic testing for individuals and families at inherited risk for cancer.

Kauff received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia. He completed his residency at New York Medical College and his Fellowship at Memorial Sloan-Kettering Cancer Center/New York Presbyterian Hospital.

Kauff’s research interests, among others, include the role of genetic counseling on the evaluation and management of women with an inherited predisposition to cancer. His clinical focus includes cancer risk counseling, screening for and prevention of inherited cancers and the gynecologic care of patients with cancer. Kauff is the principal investigator in studies evaluating the efficacy of risk-reducing salpingo-oophorectomy (RRSO) for the prevention of breast and gynecologic cancer in women with BRCA1 or BRCA2 mutations. His work includes the teaching of fellows, residents and students.